Health Care • Biotechnology: Pharmaceutical Preparations
$10.33 ▲ +0.21
(+2.08%)
MKT CAP: $593.3M • VOL: 689.0K
52W L $2 52W H $18
ROARABLE / RQD
D- • 38/100
PIOTROSKI
3 / 9
CLYM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$67.9M | -$82.0M | -$40.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$59.9M | -$73.9M | -$35.1M |
| EBITDA (Normalized) | -$67.7M | -$82.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$54.4M | -$15.6M | -$20.6M |
| Capital Expenditures (CapEx) | $186.0K | $0 | — |
| Free Cash Flow (FCF) | -$54.5M | -$15.6M | -$20.6M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -43.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $35.7M | $87.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $160.5M | $211.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CLYM.